pharmacopeia
GET
/api/v1/drug/carbachol

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: Cholinergic Muscarinic Agonists.

Cholinergic Muscarinic

Indications

Sourced from openFDA
  • Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.

Contraindications

Sourced from openFDA
  • Should not be used in those persons showing hypersensitivity to any of the components of this preparation.contraindicated

Dosage & administration

Sourced from openFDA

Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.

Warnings & precautions

Sourced from openFDA

For single-dose intraocular use only. Discard unused portion. Intraocular carbachol 0.01% should be used with caution in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. spasm, urinary tract obstruction and Parkinson's disease. The vial stopper contains natural rubber (latex) which may cause severe allergic reactions.

Adverse reactions

Sourced from openFDA

Ocular: Corneal clouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported. Systemic: Side effects such as flushing, sweating, epigastric distress, abdominal cramps, tightness in urinary bladder, and headache have been reported with topical or systemic application of carbachol. The following additional reactions have been identified during post-approval use of MIOSTAT (carbachol intraocular solution, USP) 0.01% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to MIOSTAT, or a combination of these factors, include: corneal edema, drug effect prolonged (miosis), eye inflammation, eye pain, intraocular pressure increased, ocular hyperemia, vision blurred, visual impairment, and vomiting.

Use in specific populations

Sourced from openFDA

Pregnancy: There are no adequate and well-controlled studies in pregnant women. MIOSTAT* (carbachol intraocular solution, USP) 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Approval history

Sourced from openFDA
  • Sep 28, 1972NDANDA016968Alcon
  • Jan 28, 2026NDANDA220142Visus

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
153 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Endophthalmitis2416%
  2. 2Off Label Use2114%
  3. 3Abdominal Discomfort1912%
  4. 4Amyloid Arthropathy1812%
  5. 5Arthropathy1812%
  6. 6Drug Abuse1812%
  7. 7Drug Ineffective1812%
  8. 8Intentional Product Misuse1812%
  9. 9Lower Respiratory Tract Infection1812%
  10. 10Obesity1812%
  11. 11Product Dose Omission Issue1812%
  12. 12Pulmonary Pain1812%
  13. 13Rash1812%
  14. 14Drug Dependence1711%
  15. 15Overdose1711%

Literature

View JSON

Recent PubMed references pinned to Carbachol as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 10 ClinicalTrials.gov registrations naming Carbachol as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Carbachol work?
Mechanism-of-action class: Cholinergic Muscarinic Agonists.
What is Carbachol used for?
According to FDA labeling, Carbachol carries indications including: Intraocular use for obtaining miosis during surgery. In addition, MIOSTAT* (carbachol intraocular solution, USP) 0.01% reduces the intensity of IOP elevation in the first 24 hours after cataract surgery.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Carbachol?
Carbachol is classified as Choline esters, Parasympathomimetics, Cholinergic Muscarinic Agonists, Decreased Intraocular Fluid Pressure, Pupillary Constriction.
What are the brand names for Carbachol?
Carbachol is marketed under brand names including Isopto Carbachol, Miostat, Yuvezzi.
What are the contraindications for Carbachol?
Carbachol labeling lists contraindications including: Should not be used in those persons showing hypersensitivity to any of the components of this preparation.. Always consult the full prescribing information and a clinician.
Note. Data for carbachol is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients